Axsome Therapeutics, Inc. (AXSM)

NasdaqGM: AXSM · 即時價格 · USD

198.52

-0.50 (-0.25%)

收盤價： Aug 31, 2026, 3:59 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

-0.25% (1D)

買價	170.52
市值	10.4B
營收 (ttm)	777M
淨利（ttm）	-192M
	0.73
	-3.74
	n/a
	39.44
P/B (ttm)	124.62
P/S (ttm)	13.39
財報日期	Nov 2, 2026

賣價	259.2
成交量	503,552
20 日平均成交量	861,040
開盤價	199.00
前收盤價	199.02
當日區間	197.05 - 200.74
52 週範圍	112.90 - 260.19
分析師	強<br>購買
目標價	280 (41.04%)
股利	n/a
除息日	n/a

關於 AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (so...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Nov 19, 2015

員工 1,346

證券交易所 NasdaqGM

股票代號 AXSM

網站 https://www.axsome.com

完整的公司簡介

財務表現

Axsome Therapeutics 在 2025 年的營收為 638.5M，較前一年的 385.69M 增加 65.55%。淨利為 -183.17M，較前期減少 -36.22%。

財務報表

分析師預測

根據 21 位分析師的評等，AXSM 的平均評等為「Strong Buy」。12 個月目標價為 280，較最新價格有 41.04% 的上漲空間。

股票預測

財報驚奇

Axsome Therapeutics 已於 Aug 10, 2026 公布季度財報：

營收為 $191.2M 低於預期 $0, 年增 57.42% 成長.
每股盈餘為 -0.99 低於預期 -0.21, 年增 -2.06% 下滑.

下次財報發布

Axsome Therapeutics, Inc. 的下次財報預計於 Nov 2, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

2 天前 · Motley Fool

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

1 週前 · Motley Fool

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

The company has also crushed broader equities over the past five years.

2 週前 · Zacks

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

2 週前 · Simply Wall St.

Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now?

Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net loss of US$51.31 million. Earnin...

2 週前 · Simply Wall St.

Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price?

Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the ...

第 1 頁，共 2 頁

Axsome Therapeutics, Inc. (AXSM)